{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:26:37Z","timestamp":1790652397952,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Ministry of Health, labour and Welfare","award":["23AA2003"],"award-info":[{"award-number":["23AA2003"]}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Taxanes are known to be associated with several ocular adverse events; however, large-scale data comparing the risk of ocular adverse events between the two commonly used taxanes, docetaxel (DTX) and paclitaxel (PTX), remain limited. Therefore, we aimed to compare the risks of epiphora, cystoid macular edema, and optic neuropathy between DTX- and PTX-based chemotherapy regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using a nationwide claims database in Japan, we identified 6038 patients who initiated neoadjuvant or adjuvant taxane-based chemotherapy for breast cancer between April 2014 and November 2022. Data analysis was conducted in 2024. This study was conducted across multiple referral centers and community hospitals in Japan, providing a comprehensive view of taxane-based chemotherapy practices in diverse healthcare settings. Participants included 6038 patients diagnosed with breast cancer who initiated neoadjuvant or adjuvant taxane-based chemotherapy. Eligibility criteria included female patients aged 18\u00a0years or older. Participants were selected from a nationwide claims database using a consecutive sampling method. Patients who received DTX-based chemotherapy (DTX group) were compared with those who received PTX-based chemotherapy (PTX group). After adjusting for potential confounders using a propensity score-overlap weighting method, we estimated the incidence of the three ocular adverse events and hazard ratios (HRs) using Cox proportional hazards regression models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the 6038 eligible patients, 3829 were in the DTX group and 2209 in the PTX group. The adjusted HR for epiphora in the DTX group was 1.69 [95% confidence interval (CI), 1.17 to 2.45] compared with the PTX group. For cystoid macular edema and optic neuropathy, the adjusted HRs were 0.74 (95% CI, 0.52 to 1.04) and 0.72 (0.47 to 1.11), respectively. The composite incidence of epiphora, cystoid macular edema, and optic neuropathy did not differ significantly between the DTX and PTX groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Among patients receiving taxane-based chemotherapy for breast cancer, DTX was associated with a higher risk of epiphora compared with PTX. However, the incidence rates of cystoid macular edema and optic neuropathy did not differ significantly between the two groups. These findings offer valuable insights into the ocular adverse event profile of taxane-based chemotherapy in patients with breast cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10549-025-07720-8","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T04:32:12Z","timestamp":1747110732000},"page":"173-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ocular adverse events of perioperative adjuvant docetaxel vs paclitaxel for breast cancer: propensity-score overlap-weighted analysis"],"prefix":"10.1007","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-4200","authenticated-orcid":false,"given":"Chikako","family":"Iwai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Miyawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"7720_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321:288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323","journal-title":"JAMA"},{"key":"7720_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J et al (2024) Breast cancer, Version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22:331\u2013357. https:\/\/doi.org\/10.6004\/jnccn.2024.0035","journal-title":"J Natl Compr Canc Netw"},{"key":"7720_CR3","doi-asserted-by":"publisher","first-page":"CD004421","DOI":"10.1002\/14651858.CD004421.pub3","volume":"9","author":"ML Willson","year":"2019","unstructured":"Willson ML, Burke L, Ferguson T et al (2019) Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 9:CD004421. https:\/\/doi.org\/10.1002\/14651858.CD004421.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"7720_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/cncr.30421","volume":"123","author":"T Watanabe","year":"2017","unstructured":"Watanabe T, Kuranami M, Inoue K et al (2017) Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: final results of the national surgical adjuvant study of breast cancer 02 trial, a randomized comparative phase 3 study. Cancer 123:759\u2013768. https:\/\/doi.org\/10.1002\/cncr.30421","journal-title":"Cancer"},{"key":"7720_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10549-014-3202-5","volume":"148","author":"E Saloustros","year":"2014","unstructured":"Saloustros E, Malamos N, Boukovinas I et al (2014) Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat 148:591\u2013597. https:\/\/doi.org\/10.1007\/s10549-014-3202-5","journal-title":"Breast Cancer Res Treat"},{"key":"7720_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta11400","volume":"11","author":"S Ward","year":"2007","unstructured":"Ward S, Simpson E, Davis S et al (2007) Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 11:1\u2013144. https:\/\/doi.org\/10.3310\/hta11400","journal-title":"Health Technol Assess"},{"key":"7720_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1146\/annurev.med.48.1.353","volume":"48","author":"EK Rowinsky","year":"1997","unstructured":"Rowinsky EK (1997) The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48:353\u2013374. https:\/\/doi.org\/10.1146\/annurev.med.48.1.353","journal-title":"Annu Rev Med"},{"key":"7720_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.940239","volume":"12","author":"J-I Lai","year":"2022","unstructured":"Lai J-I, Chao T-C, Liu C-Y et al (2022) A systemic review of taxanes and their side effects in metastatic breast cancer. Front Oncol 12:940239. https:\/\/doi.org\/10.3389\/fonc.2022.940239","journal-title":"Front Oncol"},{"key":"7720_CR9","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.asjsur.2021.09.048","volume":"45","author":"W Li","year":"2022","unstructured":"Li W, Lu R-H, Shih C-W (2022) Docetaxel-related toxic optic neuropathy in a patient with metastatic breast cancer. Asian J Surg 45:874\u2013876. https:\/\/doi.org\/10.1016\/j.asjsur.2021.09.048","journal-title":"Asian J Surg"},{"key":"7720_CR10","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.2147\/OTT.S65774","volume":"7","author":"Y Li","year":"2014","unstructured":"Li Y, Li Y, Li J et al (2014) Paclitaxel- and\/or cisplatin-induced ocular neurotoxicity: a case report and literature review. Onco Targets Ther 7:1361\u20131366. https:\/\/doi.org\/10.2147\/OTT.S65774","journal-title":"Onco Targets Ther"},{"key":"7720_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12886-019-1246-3","volume":"19","author":"X Yuan","year":"2019","unstructured":"Yuan X, Feng Y, Li D, Li M (2019) Unilateral visual impairment in a patient undergoing chemotherapy: a case report and clinical findings. BMC Ophthalmol 19:236. https:\/\/doi.org\/10.1186\/s12886-019-1246-3","journal-title":"BMC Ophthalmol"},{"key":"7720_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2415-15-6","volume":"15","author":"J-H Shin","year":"2015","unstructured":"Shin J-H, Kim Y-D, Woo KI, Korean Society of Ophthalmic Plastic and Reconstructive Surgery (KSOPRS) (2015) Impact of epiphora on vision-related quality of life. BMC Ophthalmol 15:6. https:\/\/doi.org\/10.1186\/1471-2415-15-6","journal-title":"BMC Ophthalmol"},{"key":"7720_CR13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamaophthalmol.2022.3026","volume":"140","author":"M Sodhi","year":"2022","unstructured":"Sodhi M, Yeung SN, Maberley D et al (2022) Risk of ocular adverse events with taxane-based chemotherapy. JAMA Ophthalmol 140:880\u2013884. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.3026","journal-title":"JAMA Ophthalmol"},{"key":"7720_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1592\/phco.26.6.853","volume":"26","author":"PE Kintzel","year":"2006","unstructured":"Kintzel PE, Michaud LB, Lange MK (2006) Docetaxel-associated epiphora. Pharmacotherapy 26:853\u2013867. https:\/\/doi.org\/10.1592\/phco.26.6.853","journal-title":"Pharmacotherapy"},{"key":"7720_CR15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40265-013-0055-x","volume":"73","author":"OE Makri","year":"2013","unstructured":"Makri OE, Georgalas I, Georgakopoulos CD (2013) Drug-induced macular edema. Drugs 73:789\u2013802. https:\/\/doi.org\/10.1007\/s40265-013-0055-x","journal-title":"Drugs"},{"key":"7720_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.31083\/j.fbl2706171","volume":"27","author":"Y-T Ye","year":"2022","unstructured":"Ye Y-T, Zhou Z-Y, Wen L-S et al (2022) The significance of the ocular adverse effect induced by systemic taxane application. Front Biosci (Landmark Ed) 27:171. https:\/\/doi.org\/10.31083\/j.fbl2706171","journal-title":"Front Biosci (Landmark Ed)"},{"key":"7720_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/cncr.11527","volume":"98","author":"B Esmaeli","year":"2003","unstructured":"Esmaeli B, Hidaji L, Adinin RB et al (2003) Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 98:504\u2013507. https:\/\/doi.org\/10.1002\/cncr.11527","journal-title":"Cancer"},{"key":"7720_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/1756-0500-7-322","volume":"7","author":"T Yamagishi","year":"2014","unstructured":"Yamagishi T, Ochi N, Yamane H et al (2014) Epiphora in lung cancer patients receiving docetaxel: a case series. BMC Res Notes 7:322. https:\/\/doi.org\/10.1186\/1756-0500-7-322","journal-title":"BMC Res Notes"},{"key":"7720_CR19","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/s0161-6420(02)00989-2","volume":"109","author":"B Esmaeli","year":"2002","unstructured":"Esmaeli B, Hortobagyi GN, Esteva FJ et al (2002) Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 109:1188\u20131191. https:\/\/doi.org\/10.1016\/s0161-6420(02)00989-2","journal-title":"Ophthalmology"},{"key":"7720_CR20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/s0161-6420(00)00640-0","volume":"108","author":"B Esmaeli","year":"2001","unstructured":"Esmaeli B, Valero V, Ahmadi MA, Booser D (2001) Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology 108:994\u2013995. https:\/\/doi.org\/10.1016\/s0161-6420(00)00640-0","journal-title":"Ophthalmology"},{"key":"7720_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/IOP.0b013e318032e908","volume":"23","author":"E McCartney","year":"2007","unstructured":"McCartney E, Valluri S, Rushing D, Burgett R (2007) Upper and lower system nasolacrimal duct stenosis secondary to paclitaxel. Ophthalmic Plast Reconstr Surg 23:170\u2013171. https:\/\/doi.org\/10.1097\/IOP.0b013e318032e908","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"7720_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","volume":"5","author":"J Verweij","year":"1994","unstructured":"Verweij J, Clavel M, Chevalier B (1994) Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): not simply two of a kind. Ann Oncol 5:495\u2013505. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a058903","journal-title":"Ann Oncol"},{"key":"7720_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/00002018-200023050-00005","volume":"23","author":"LB Michaud","year":"2000","unstructured":"Michaud LB, Valero V, Hortobagyi G (2000) Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 23:401\u2013428. https:\/\/doi.org\/10.2165\/00002018-200023050-00005","journal-title":"Drug Saf"},{"key":"7720_CR24","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1177\/1120672120969045","volume":"32","author":"BH Fortes","year":"2022","unstructured":"Fortes BH, Liou H, Dalvin LA (2022) Ophthalmic adverse effects of taxanes: the Mayo clinic experience. Eur J Ophthalmol 32:602\u2013611. https:\/\/doi.org\/10.1177\/1120672120969045","journal-title":"Eur J Ophthalmol"},{"key":"7720_CR25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.31662\/jmaj.2021-0189","volume":"5","author":"A Okada","year":"2022","unstructured":"Okada A, Yasunaga H (2022) Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. JMA J 5:190\u2013198. https:\/\/doi.org\/10.31662\/jmaj.2021-0189","journal-title":"JMA J"},{"key":"7720_CR26","doi-asserted-by":"publisher","DOI":"10.37737\/ace.25006","author":"H Yasunaga","year":"2025","unstructured":"Yasunaga H (2025) DeSC database. Ann Clin Epidemiol. https:\/\/doi.org\/10.37737\/ace.25006","journal-title":"Ann Clin Epidemiol"},{"key":"7720_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ophtha.2022.10.017","volume":"130","author":"Y Hashimoto","year":"2023","unstructured":"Hashimoto Y, Yamana H, Iwagami M et al (2023) Ocular adverse events after coronavirus disease 2019 mRNA vaccination: matched cohort and self-controlled case series studies using a large database. Ophthalmology 130:256\u2013264. https:\/\/doi.org\/10.1016\/j.ophtha.2022.10.017","journal-title":"Ophthalmology"},{"key":"7720_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000002152","author":"A Fujita","year":"2022","unstructured":"Fujita A, Aoyama Y, Yamana H et al (2022) Validity of algorithms to identify patients with glaucoma using the Japanese claims data. J Glaucoma. https:\/\/doi.org\/10.1097\/IJG.0000000000002152","journal-title":"J Glaucoma"},{"key":"7720_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5657","volume":"367","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Franklin JM (2019) Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ 367:l5657. https:\/\/doi.org\/10.1136\/bmj.l5657","journal-title":"BMJ"},{"key":"7720_CR30","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","volume":"323","author":"LE Thomas","year":"2020","unstructured":"Thomas LE, Li F, Pencina MJ (2020) Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA 323:2417\u20132418. https:\/\/doi.org\/10.1001\/jama.2020.7819","journal-title":"JAMA"},{"key":"7720_CR31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwy201","volume":"188","author":"F Li","year":"2019","unstructured":"Li F, Thomas LE, Li F (2019) Addressing extreme propensity scores via the overlap weights. Am J Epidemiol 188:250\u2013257. https:\/\/doi.org\/10.1093\/aje\/kwy201","journal-title":"Am J Epidemiol"},{"key":"7720_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.37737\/ace.22013","volume":"4","author":"Y Hashimoto","year":"2022","unstructured":"Hashimoto Y, Yasunaga H (2022) Theory and practice of propensity score analysis. Ann Clin Epidemiol 4:101\u2013109. https:\/\/doi.org\/10.37737\/ace.22013","journal-title":"Ann Clin Epidemiol"},{"key":"7720_CR33","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083\u20133107. https:\/\/doi.org\/10.1002\/sim.3697","journal-title":"Stat Med"},{"key":"7720_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2622","volume":"350","author":"JM Bland","year":"2015","unstructured":"Bland JM, Altman DG (2015) Statistics notes: bootstrap resampling methods. BMJ 350:h2622. https:\/\/doi.org\/10.1136\/bmj.h2622","journal-title":"BMJ"},{"key":"7720_CR35","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC (2014) The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 33:1242\u20131258. https:\/\/doi.org\/10.1002\/sim.5984","journal-title":"Stat Med"},{"key":"7720_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ctrv.2015.11.009","volume":"43","author":"L Biganzoli","year":"2016","unstructured":"Biganzoli L, Aapro M, Loibl S et al (2016) Taxanes in the treatment of breast cancer: have we better defined their role in older patients? A position paper from a SIOG task force. Cancer Treat Rev 43:19\u201326. https:\/\/doi.org\/10.1016\/j.ctrv.2015.11.009","journal-title":"Cancer Treat Rev"},{"key":"7720_CR37","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1111\/tbj.14123","volume":"26","author":"L Pabst","year":"2020","unstructured":"Pabst L, Velten M, Fischbach C et al (2020) Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer. Breast J 26:2376\u20132382. https:\/\/doi.org\/10.1111\/tbj.14123","journal-title":"Breast J"},{"key":"7720_CR38","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1001\/jama.2016.17700","volume":"316","author":"BF Arnold","year":"2016","unstructured":"Arnold BF, Ercumen A (2016) Negative control outcomes: a tool to detect bias in randomized trials. JAMA 316:2597\u20132598. https:\/\/doi.org\/10.1001\/jama.2016.17700","journal-title":"JAMA"},{"key":"7720_CR39","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/01.IOP.0000075016.29682.E0","volume":"19","author":"B Esmaeli","year":"2003","unstructured":"Esmaeli B, Burnstine MA, Ahmadi MA, Prieto VG (2003) Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Ophthalmic Plast Reconstr Surg 19:305\u2013308. https:\/\/doi.org\/10.1097\/01.IOP.0000075016.29682.E0","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"7720_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.22336\/rjo.2023.21","volume":"67","author":"EA Stoicescu","year":"2023","unstructured":"Stoicescu EA, Cherecheanu AP (2023) Meibomian gland changes in breast cancer patients treated with docetaxel-partial results. Rom J Ophthalmol 67:111\u2013116. https:\/\/doi.org\/10.22336\/rjo.2023.21","journal-title":"Rom J Ophthalmol"},{"key":"7720_CR41","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1200\/JCO.2012.45.6574","volume":"31","author":"A Chan","year":"2013","unstructured":"Chan A, Su C, de Boer RH, Gajdatsy A (2013) Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. J Clin Oncol 31:2123\u20132127. https:\/\/doi.org\/10.1200\/JCO.2012.45.6574","journal-title":"J Clin Oncol"},{"key":"7720_CR42","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/02713683.2023.2219041","volume":"48","author":"G McGwin","year":"2023","unstructured":"McGwin G, Contorno T, Vicinanzo MG, Owsley C (2023) The association between taxane use and lacrimal disorders. Curr Eye Res 48:873\u2013877. https:\/\/doi.org\/10.1080\/02713683.2023.2219041","journal-title":"Curr Eye Res"},{"key":"7720_CR43","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-suppl_2-3","author":"J Gligorov","year":"2004","unstructured":"Gligorov J, Lotz JP (2004) Preclinical pharmacology of the taxanes: implications of the differences. The Oncol. https:\/\/doi.org\/10.1634\/theoncologist.9-suppl_2-3","journal-title":"The Oncol"},{"key":"7720_CR44","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1111\/all.15825","volume":"78","author":"I Ogulur","year":"2023","unstructured":"Ogulur I, Yazici D, Pat Y et al (2023) Mechanisms of gut epithelial barrier impairment caused by food emulsifiers polysorbate 20 and polysorbate 80. Allergy 78:2441\u20132455. https:\/\/doi.org\/10.1111\/all.15825","journal-title":"Allergy"},{"key":"7720_CR45","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1590\/fst.19620","volume":"41","author":"A Yeboah","year":"2020","unstructured":"Yeboah A, Ying S, Lu J et al (2020) Castor oil (Ricinus communis): a review on the chemical composition and physicochemical properties. Food Sci Technol 41:399\u2013413. https:\/\/doi.org\/10.1590\/fst.19620","journal-title":"Food Sci Technol"},{"key":"7720_CR46","doi-asserted-by":"publisher","first-page":"E29","DOI":"10.1097\/NCC.0000000000000135","volume":"38","author":"H-S Wu","year":"2015","unstructured":"Wu H-S, Harden JK (2015) Symptom burden and quality of life in survivorship: a review of the literature. Cancer Nurs 38:E29-54. https:\/\/doi.org\/10.1097\/NCC.0000000000000135","journal-title":"Cancer Nurs"},{"key":"7720_CR47","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s11764-015-0512-5","volume":"10","author":"JE Fardell","year":"2016","unstructured":"Fardell JE, Thewes B, Turner J et al (2016) Fear of cancer recurrence: a theoretical review and novel cognitive processing formulation. J Cancer Surviv 10:663\u2013673. https:\/\/doi.org\/10.1007\/s11764-015-0512-5","journal-title":"J Cancer Surviv"},{"key":"7720_CR48","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3892\/mco.2017.1296","volume":"7","author":"E Bassi","year":"2017","unstructured":"Bassi E, Loizzi V, Furino C et al (2017) Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: a case report. Mol Clin Oncol 7:285\u2013287. https:\/\/doi.org\/10.3892\/mco.2017.1296","journal-title":"Mol Clin Oncol"},{"key":"7720_CR49","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/archopht.125.5.709","volume":"125","author":"MM Joshi","year":"2007","unstructured":"Joshi MM, Garretson BR (2007) Paclitaxel maculopathy. Arch Ophthalmol 125:709\u2013710. https:\/\/doi.org\/10.1001\/archopht.125.5.709","journal-title":"Arch Ophthalmol"},{"key":"7720_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10792-012-9558-9","volume":"32","author":"TI Kuznetcova","year":"2012","unstructured":"Kuznetcova TI, Cech P, Herbort CP (2012) The mystery of angiographically silent macular oedema due to taxanes. Int Ophthalmol 32:299\u2013304. https:\/\/doi.org\/10.1007\/s10792-012-9558-9","journal-title":"Int Ophthalmol"},{"key":"7720_CR51","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ics.2004.11.065","volume":"1278","author":"V Scaioli","year":"2005","unstructured":"Scaioli V, Caraceni A, Martini C et al (2005) Visual electrophysiological evaluation in paclitaxel-treated patients. Pathophysiological mechanisms involved in retinal and optic nerve dysfunctions. Int Congr Ser 1278:37\u201340. https:\/\/doi.org\/10.1016\/j.ics.2004.11.065","journal-title":"Int Congr Ser"},{"key":"7720_CR52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2415-14-18","volume":"14","author":"TP Moloney","year":"2014","unstructured":"Moloney TP, Xu W, Rallah-Baker K et al (2014) Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report. BMC Ophthalmol 14:18. https:\/\/doi.org\/10.1186\/1471-2415-14-18","journal-title":"BMC Ophthalmol"},{"key":"7720_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1167\/iovs.13-12840","volume":"54","author":"IK Gipson","year":"2013","unstructured":"Gipson IK (2013) Age-related changes and diseases of the ocular surface and cornea. Invest Ophthalmol Vis Sci 54:48\u201353. https:\/\/doi.org\/10.1167\/iovs.13-12840","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7720_CR54","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1200\/JCO.2005.04.4453","volume":"24","author":"B Esmaeli","year":"2006","unstructured":"Esmaeli B, Amin S, Valero V et al (2006) Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol 24:3619\u20133622. https:\/\/doi.org\/10.1200\/JCO.2005.04.4453","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07720-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07720-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07720-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T07:24:06Z","timestamp":1747553046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07720-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7720"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07720-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Miyawaki reported receiving consulting fees from M3, Inc and Datack, Inc., lecture fees from Janssen Pharma (in the last 36\u00a0months), and grants from the Health Care Science Institute (2023\u20132024), Organization of Data for Social Transformation (2023\u20132025), the Ministry of Health Labour and Welfare (Health Labour Sciences Research Grant), and Japan Society for the Promotion of Science (24K02701), outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of the University of Tokyo, which waived the requirement for informed consent due to the anonymity of the patient database (approval number: 2021010NI). The research was conducted in accordance with the principles of the Declaration of Helsinki and its subsequent amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}